Navigation Links
Abbott Completes Visiogen Acquisition
Date:10/20/2009

ABBOTT PARK, Ill., Oct. 20 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced that it has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.

Visiogen's Synchrony® accommodating IOL is a significant advancement in artificial lens technology. It is designed to mimic the eye's natural ability to change focus (accommodation), delivering improved vision at all distances, potentially eliminating the need for glasses or contact lenses, reducing glare and nighttime halos, and improving contrast sensitivity.

Abbott's $400 million cash purchase of Visiogen boosts the company's presence in the vision care segment, which it entered in February 2009 with its acquisition of Advanced Medical Optics. Abbott Medical Optics offers a range of cataract, refractive and corneal products designed to meet the needs of patients who suffer from a wide range of vision disorders and seek greater freedom from the limitations of eyeglasses.

"Visiogen immediately provides Abbott Medical Optics with a talented team of dedicated professionals and an entry point into the accommodating IOL market," said Jim Mazzo, senior vice president, Abbott Medical Optics. "The innovative Synchrony accommodating IOL expands our diverse portfolio of cataract treatments and allows Abbott the opportunity to help the more than 1 billion people worldwide suffering from presbyopia."

Synchrony has received CE mark designation and has been available commercially in Europe since January 2009. It also is currently under review by the U.S. Food and Drug Administration (FDA).

Intraocular lenses are implanted in a patient's eye after the removal of the na
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Rock Creek Pharmaceuticals, Inc. (NASDAQ: ... announced that the Food and Drug Administration ("FDA"), has ... on RCP,s Investigational New Drug ("IND") application before granting ... the US. Dr. Chris Chapman , ... comments on our IND. When we receive the agency,s ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... GREEN BAY, Wis., Sept. 16 Top researchers at ... Center in Dallas are exploring the clinical applications of ... potency, and bioavailability. Previous studies have ... than other forms of curcumin, and had a retention ...
... Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic... -- REGENSBURG, Germany, September ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
Cached Medicine Technology:BCM-95 Demonstrates Superior Anti-Inflammatory Effects 2Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 2Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 3Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 4Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 5Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 6Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 7Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 8
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... 2014 Recently, MyDressCity.com, one of the ... occasion outfits, has released its new range of ... products are available at discounted prices. Worldwide clients can ... , In the company’s online shop, there are plenty ... are made with great materials. MyDressCity.com’s hot items are ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... , NAPA, Calif., Aug. 19 Dey ... today issued an advisory regarding two lots of its Albuterol Sulfate ... that was stolen in McKinney, Texas. , , ... brand name "DEY" and contains thirty 3ml single-dose vials. The lot ...
... , , , ... released the following statement after President Obama said that it,s ... the health care reform plans. , , ... "Tonight, President Obama deliberately misled the American people by ...
... , , , ... one of four companies to have been awarded a contract to ... The contract becomes effective October 1, 2009. , , ... work with the State of Arizona and offer our innovative health ...
... Aug. 19 (HealthDay News) -- People with lung cancer who ... a drug called Tarceva, which is believed to work well ... who take the drug, new research has found. , According ... 20 issue of the New England Journal of Medicine ...
... NEW YORK, Aug. 19 One of the few bright spots of ... and HBA Global Expo ( www.hb a e ... activists to deliver a Keynote Presentations on Tuesday, September 15, 2009 at ... New York. Horst M. Rechelbacher, founder of Intelligent Nutrients and ...
... a novel robot-assisted endoscopic technique, a team of surgeons ... has successfully treated 200 consecutive patients with thyroid cancer. ... cosmetic benefits that the traditional open operation does not ... Journal of the American College of Surgeons . ...
Cached Medicine News:Health News:Dey Issues Advisory 2Health News:President Obama Misleads on Abortion Funding in Health Care Reform 2Health News:CIGNA Awarded State of Arizona Health Care Contract 2Health News:Gene Mutation Improves Response to Lung Cancer Drug 2Health News:Gene Mutation Improves Response to Lung Cancer Drug 3Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 2Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 3Health News:New robot-assisted surgical method found successful for treatment of thyroid cancer 2
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: